BCRX Financial Facts

Loss on foreign currency derivative: -931K
Net loss: -11.53M
See Full Income Statement

Deferred collaboration revenue: 2.28M
Interest payable: 7.56M
See Full Balance Sheet

BioCryst Pharmaceuticals, Inc. (BCRX) Earnings

  |   Expand Research on BCRX
Next EPS Date 2/22/17 *Est. EPS Growth Rate +20.0% *Last Qtr.
Average EPS % Beat Rate +4.4% Revenue Growth Rate -29.1% *Last Qtr.
Average % Move 1-Wk after EPS +11.8% Normal Earnings Time Before Open
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. 1-Week % 1-Day % Details
11/7/16 Q316 -$0.16-$0.24 +$0.08$7.8M$5.94M N/A Details
8/4/16 Q216 -$0.22-$0.26 +$0.04$4.8M$3.92M N/A Details
5/5/16 Q116 -$0.31-$0.23 -$0.08$4.82M$5.42M N/A Details
2/23/16 Q415 -$0.25-$0.26 +$0.01$4.6M$6.34M N/A Details
11/5/15 Q315 -$0.20-$0.20 $0.00$11M$6.77M N/A Details
8/7/15 Q215 $0.07-$0.22 +$0.29$25.8M$7.1M N/A Details
5/8/15 Q115 -$0.21-$0.25 +$0.04$6.8M$4.3M N/A Details
2/18/15 Q414 -$0.16-$0.21 +$0.05$5.4M$3.64M N/A Details